동아에스티

170900KOSPI

49.5 / 100

Reference Date: 2026-10-23

Financial Score20.0 / 40

News Sentiment12.5 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but ROE is below the industry average. Roughly flat over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Dong-A ST, established in 2013 through a spin-off from Dong-A Pharmaceutical, focuses on manufacturing and selling specialty pharmaceuticals, medical devices, and pharmaceutical cosmetics. Key products include Grotrixin, Motiriton, and Suganon, with 2024 sales reaching 697.9 billion won, a 5.1% increase from the previous year. Growth was driven by the biopharmaceutical product Grotrixin and increased overseas exports.

Number of Employees

1,685people

Average Salary

78.9M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

0.51Industry Average 1.207.0Point

Half of industry avg (excellent)

ROE

-5.45Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

49.87Industry Average 100.006.5Point

Half of industry avg (excellent)

Trend 2023~20252.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲10.5% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼110.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -2.8% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (14%, downtrend)

Current 35,350Won52-week high 55,12552-week low 32,000

1-month return3.0Point

1m -0.56% (flat)

Volume trend3.0Point

Volume flat

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral기업설명회(IR)개최(안내공시)2026-10-22
Neutral결산실적공시예고(안내공시)2026-10-22
Neutral주식등의대량보유상황보고서(일반)2026-10-22